(IN BRIEF) Sanofi’s experimental CD40L antibody, frexalimab, demonstrates encouraging results in a 48-week phase 2 study for relapsing multiple sclerosis (MS). Presented at the American Academy of Neurology Annual Meeting, the data reveals sustained reduction in disease activity and favorable … Read the full press release
Posted in Business, Education, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged CD40L antibody, Erik Wallström, Frexalimab, multiple sclerosis, Patrick Vermersch, safety, Sanofi
(IN BRIEF) Evotec SE announces the appointment of Aurélie Dalbiez as their new Chief People Officer (CPO), effective June 15, 2024. Joining the Management Board, Aurélie brings over 25 years of international Human Resources leadership experience, previously serving as the … Read the full press release
Posted in Business, Germany, Industrial, Management, News, Pharma & Biotech, Science, Technology
Tagged appointment, Aurélie Dalbiez, Chief People Officer, Dr Mario Polywka, Evotec, leadership
(IN BRIEF) Novartis revealed promising data from the ALITHIOS open-label extension study, highlighting the enduring effectiveness of Kesimpta® (ofatumumab) in treating relapsing multiple sclerosis (RMS) over a span of up to six years. The study, presented at the American Academy … Read the full press release
(IN BRIEF) AstraZeneca’s IMPACT CKD model predicts a significant increase in chronic kidney disease (CKD) across eight countries, with up to 16.5% of the population affected by 2032, including a substantial rise in advanced-stage cases. Presented at the 2024 ISN … Read the full press release
(IN BRIEF) Bosch and Randox Laboratories Ltd. have forged a strategic partnership aimed at transforming molecular diagnostics with a focus on the Vivalytic analysis platform. With an investment of 150 million euros in joint research, development, and distribution, the collaboration … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Ireland, Management, News, Pharma & Biotech, Science, Technology
Tagged Bosch, Dr. Peter Fitzgerald, Healthcare, Marc Meier, Molecular Diagnostics, partnership, Randox Labs, Stefan Hartung
(IN BRIEF) The European Bank for Reconstruction and Development (EBRD) has provided a €22 million loan to Ukrainian pharmaceutical giant Farmak Group to facilitate its strategic acquisition of a Polish pharmaceutical company and to upgrade its IT systems. Farmak, a … Read the full press release
Posted in Banks, Business, Economy, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Poland, Science, Technology, Ukraine, United Kingdom
Tagged acquisition, EBRD, expansion, Farmak, Frederic Lucenet, investment, partnership, Poland, sustainability, UKRAINE
(IN BRIEF) WACKER’s mRNA competence center in Halle is gearing up to produce an active ingredient for combatting acute respiratory distress syndrome (ARDS) in collaboration with Pantherna Therapeutics. The center, equipped with four new production lines, will more than triple … Read the full press release
Posted in Business, Chemicals, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged ARDS Treatment, Dr. Guido Seidel, Dr. Jörg Kaufmann, mRNA Production, PAN004, Pantherna, partnership, sustainability, WACKER
(IN BRIEF) AstraZeneca announces positive outcomes from the ADRIATIC Phase III trial, revealing that its immunotherapy drug Imfinzi (durvalumab) demonstrated a significant improvement in overall survival (OS) and progression-free survival (PFS) among patients with limited-stage small cell lung cancer (LS-SCLC) … Read the full press release
(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for ZEVTERA® (ceftobiprole medocaril sodium for injection). The approval covers its use in adult patients with Staphylococcus aureus bloodstream infections (bacteremia), … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Adesh Kaul, Basilea, David Veitch, Dr. Marc Engelhardt, FDA, Pediatric Use, safety, Severe Bacterial Infections, Thomas Holland, Vance G. Fowler, Zevtera®
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acknowledged by the US FDA for treating adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received prior systemic … Read the full press release
Posted in Business, Education, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Biologics License Application (BLA), Breast Cancer Treatment, Daiichi Sankyo, datopotamab deruxtecan, Japan, Ken Takeshita, partnership, safety, Susan Galbraith, sustainability, US FDA
(IN BRIEF) AstraZeneca and Sanofi celebrate the approval of Beyfortus (nirsevimab) in Japan by the Ministry of Health, Labour, and Welfare for preventing lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in neonates, infants, and children entering … Read the full press release
Posted in Business, Environment, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Beyfortus, Dr. Hiroyuki Moriuchi, France, Iskra Reic, Japan, LRTD, partnership, prophylaxis, respiratory syncytial virus, safety, Sanofi, sustainability
(IN BRIEF) AstraZeneca announces the approval of Truqap (capivasertib) in combination with Faslodex (fulvestrant) by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating adult patients with unresectable or recurrent hormone receptor-positive, HER2-negative breast cancer. The approval, based … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Breast Cancer Treatment, Dave Fredrickson, Faslodex, Japan, Masakazu Toi, MHLW, safety, Truqap
(IN BRIEF) Merck, a prominent science and technology company, announces a €14 million expansion of its M LabTM Collaboration Center in Shanghai, bolstering its support for the biopharmaceutical industry in China. The expansion includes new facilities such as a biology … Read the full press release
Posted in Business, Construction, Environment, Financial, Germany, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged biopharmaceutical, CHINA, Dr. Roy Wu, M LabTM Center, Merck, partnership, Shanghai, sustainability
(IN BRIEF) DPI, BII, and the EBRD have reached a binding agreement to fully exit their investment in KELIX bio, a pan-African biopharmaceutical platform, through its acquisition by Mubadala Investment Company. Founded in 2020, KELIX bio has rapidly grown to … Read the full press release
Posted in Banks, Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, Africa, Alhadi Alwazir, British International Investment (BII), Development Partners International (DPI), EBRD, Essam Farouk, Frederic Lucenet, Hocine Sidi Said, KELIX bio, Mubadala, partnership, pharmaceuticals, Samir Abhyankar, Sofiane Lahmar, sustainability
(IN BRIEF) EQT Life Sciences proudly announces Novo Nordisk’s acquisition of Cardior Pharmaceuticals, valuing the biopharmaceutical company at up to EUR 1.025 billion. Based in Hannover, Germany, Cardior specializes in RNA-based therapeutics for cardiovascular diseases, focusing initially on heart failure. … Read the full press release
Posted in Business, Denmark, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged acquisition, Cardior Pharmaceuticals, Christoph Broja, Claudia Ulbrich, Denmark, EQT, EQT Life Sciences, Germany, Heart Diseases, Novo Nordisk, partnership, Professor Thomas Thum, RNA Therapies, sustainability
(IN BRIEF) Ultomiris (ravulizumab-cwvz) has gained approval from the FDA as the inaugural long-acting C5 complement inhibitor for treating adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). The approval, based on the CHAMPION-NMOSD Phase III trial’s … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AQP4 Ab+, AstraZeneca, Marc Dunoyer, neuromyelitis optica spectrum disorder (NMOSD), safety, Sean J. Pittock, treatment, Ultomiris, USFDA
(IN BRIEF) Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorization for Fabhalta® (iptacopan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who … Read the full press release
(IN BRIEF) Breakpoint Therapeutics GmbH, a company focused on developing drugs targeting the DNA Damage Response (DDR), has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ), for the treatment of solid tumors. … Read the full press release
(IN BRIEF) Evonik has been honored with the Asia-Pacific Bioprocessing Excellence Award (ABEA) for the second consecutive year, specifically in the category of Best New Bioprocessing Supplier Award: Upstream Processing, for its Cell Culture Solutions portfolio. As a crucial component … Read the full press release
(IN BRIEF) EQT Life Sciences announces the acquisition of its portfolio company, Amolyt Pharma, by Alexion, AstraZeneca Rare Diseases, for a total deal value of $1.05 billion. This acquisition underscores Amolyt’s significant advancements in developing novel treatments for rare endocrine … Read the full press release
Posted in Business, Environment, European Union, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, Alexion, Amolyt Pharma, AstraZeneca Rare Diseases, Eneboparatide, EQT Life Sciences, Felice Verduyn-van Weegen, Healthcare, hypoparathyroidism, partnership, sustainability, Thierry Abribat
(IN BRIEF) The joint venture, Evonik Vland Biotech, established by Evonik China and Shandong Vland Biotech, officially commenced operations in Binzhou, China, aiming to bolster the market presence of probiotics for livestock gut health in the Greater China region while … Read the full press release
Posted in Business, Chemicals, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Animal Gut Health Solutions, Arron Chen, Dr. Xu Wang, Evonik, Evonik China and Shandong Vland Biotech, Evonik Vland Biotech, Johann-Caspar Gammelin, partnership, sustainability, Vland Group
(IN BRIEF) Evonik’s EUDRAGIT® polymers, renowned coatings for pharmaceuticals, celebrate 70 years of revolutionizing drug delivery. With over 23,000 patents and 10,000 scientific publications, these methacrylate polymers have become industry standards, employed in formulations for modified drug release across 80 … Read the full press release
Posted in Business, Chemicals, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged 70 Years, EUDRAGIT® Polymers, Evonik, INNOVATION, partnership, Paul Spencer, Pharmaceutical, sustainability, Thomas Riermeier
(IN BRIEF) Tubulis has closed an oversubscribed €128 million ($138.8 million) Series B2 financing round, co-led by EQT Life Sciences and Nextech Invest Ltd, with participation from new and existing investors including Frazier Life Sciences and Deep Track Capital. The … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged ADC Pipeline, cancer treatment, Christoph Broja, Deep Track Capital, Dominik Schumacher, EQT Life Sciences, Frazier Life Sciences, John de Koning, Kanishka Pothula, Nextech Invest Ltd, partnership, sustainability, TUB-030, TUB-040, Tubulis
(IN BRIEF) Health Canada has approved functional claims for Novonesis’ probiotic strain CLEPIUS™, acknowledging its efficacy in alleviating symptoms of irritable bowel syndrome (IBS) and improving quality of life in adults. The authorization encompasses a range of benefits, including relief … Read the full press release
Posted in Business, Denmark, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged abdominal pain, CLEPIUS™, diarrhea, Digestive Discomfort, Health Canada, irritable bowel syndrome (IBS), Jakob D. Rasmussen, Niklas Larsson, Novonesis, partnership, probiotic strain, stress, sustainability
(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged 8th annual Patients as Partners® Europe, AbbVie, Anders Lassen, Andrew Garvey, Annie Gilbert, Astellas, AstraZeneca, Biotech, Boehringer Ingelheim, clinical operations, clinical research, clinical trials, Conference, David James, decentralized clinical trials, Derek Stewart, diversifying clinical trials, diversity, drug development, England, GSK, Health Equity, inclusivity, inclusivity in clinical research, Ipsen, LGBTQ+ oncology, Lisa Kerr, London, Lundbeck, Novartis, Novo Nordisk, Oleksandr Gorbenko, Parexel, Patient Advocacy, patient engagment, patient experience mapping, Patrick Gallogly, Pfizer, pharma, Plaisterers’ Hall, Prostate Cancer Research, Rosamund Round, Sanofi, Sarah Zenner Dolan, Stephen Head, The Conference Forum, Valerie Bowling, Victoria DiBiaso, , Alfred Samuel
(IN BRIEF) In a groundbreaking Phase 2b study, amlitelimab demonstrates remarkable potential in maintaining treatment response for patients with moderate to severe atopic dermatitis (AD). Presented at the American Academy of Dermatology (AAD) 2024 Conference, the study reveals sustained improvement … Read the full press release
(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed at advancing the development and commercialization of Sosei Heptares’ portfolio of first-in-class GPR52 agonists. The focus of this collaboration lies … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Boehringer Ingelheim, GPR52 agonists, Hugh Marston, Matt Barnes, mental health, partnership, schizophrenia, Sosei Heptares, sustainability, treatment
(IN BRIEF) Fresenius Management SE has extended Sara Hennicken’s term as Chief Financial Officer (CFO) until 2027, two years earlier than planned, to ensure continuity in advancing the #FutureFresenius strategy. Hennicken, who joined Fresenius in 2019, has been instrumental in … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Management, Pharma & Biotech, Technology
Tagged #FutureFresenius, CFO, Chief Financial Officer, Deutsche Bank, finance, Fresenius, Fresenius Helios, Fresenius Kabi, Fresenius Management SE, Fresenius Medical Care, Sara Hennicken, Supervisory Board, transparency, Wolfgang Kirsch
(IN BRIEF) Fresenius Kabi announces FDA approval of Tyenne® (tocilizumab-aazg), the first tocilizumab biosimilar offering both IV and subcutaneous formulations. This marks a significant milestone in the company’s growth strategy (#FutureFresenius) and expands treatment options for inflammatory, autoimmune diseases, and … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged #FutureFresenius, Actemra®, autoimmune diseases, Biosimilar, Cancer, cancer treatment, FDA, Food and Drug Administration, Fresenius Kabi, Genentech, Idacio®, inflammatory, inflammatory diseases, IV, IV formulation, Stimufend®, Subcutaneous formulation, subcutaneous tocilizumab biosimilar, tocilizumab, tocilizumab biosimilar, tocilizumab-aazg, Tyenne®
(IN BRIEF) GSK has announced encouraging findings from the interim analysis of the DREAMM-8 phase III trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex) compared to the standard of care, bortezomib plus PomDex, for relapsed or … Read the full press release
(IN BRIEF) Novo Nordisk is conducting a Capital Markets Day (CMD) to provide updates on its Strategic Aspirations 2025. The event will focus on various aspects, including corporate strategy, sustainability, research and development pipeline, and financial performance. Highlights include discussions … Read the full press release
Posted in Business, Denmark, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology
Tagged Capital Markets Day, Novo Nordisk, Strategic Aspirations 2025
(IN BRIEF) Evotec and Claris Ventures have formed a strategic partnership to accelerate the progress of biotech ventures in Claris’s portfolio into clinical trials. This collaboration allows Claris’s portfolio companies, focused on biotech ventures nearing clinical trials, streamlined access to … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Italy, Pharma & Biotech, Science, Technology
(IN BRIEF) Novo Nordisk has announced promising headline results from the kidney outcomes trial FLOW, which compared injectable semaglutide 1.0 mg with placebo as an adjunct to standard care for people with type 2 diabetes and chronic kidney disease (CKD). … Read the full press release
Posted in Business, Denmark, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Flow, Kidney, Martin Holst Lange, Novo Nordisk, Ozempic, Semaglutide
(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release
Posted in Finland, Germany, Healthcare, Insurance, News, Pharma & Biotech, Science, Society, Switzerland, Technology, United Kingdom
Tagged accessible cancer solutions, AstraZeneca, Aviva, BioNTech, breast cancer, breast cancer screening, cancer care, cancer diagnostics, cancer prevention awareness, cancer research, cancer treatment, colorectal cancer, Daiichi Sankyo, datopotamab deruxtecan, Duality Biologics, Eckert & Ziegler, EMA, FDA, genetic risk information, Inspirna, lung cancer, Merck KGaA, multi-cancer early detection, neuroendocrine neoplasms diagnostics, Novartis, ompenaclid, oncology, polygenic risk score, preventive healthcare, Professor Tim Maughan, ReSisTrace methodology, Stage III EGFR-mutated lung cancer, Swiss Re Institute, Tagrisso, treatment-resistant cancer cells, University of Helsinki, University of Liverpool
(IN BRIEF) The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for datopotamab deruxtecan (Dato-DXd), developed by AstraZeneca and Daiichi Sankyo, for the treatment of nonsquamous non-small cell lung cancer (NSCLC) and hormone receptor (HR)-positive, HER2-negative breast … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Daiichi Sankyo, datopotamab deruxtecan, EMA, Ken Takeshita, Lung and Breast Cancer Treatment, Marketing Authorisation, Susan Galbraith
(IN BRIEF) Novartis has presented compelling data from the SMART study, reinforcing the clinical advantages of Zolgensma® (onasemnogene abeparvovec) in treating spinal muscular atrophy (SMA) patients weighing ≥ 8.5 kg to ≤ 21 kg, with a mean age of 4.69 … Read the full press release
(IN BRIEF) Eckert & Ziegler, in collaboration with Novartis Pharma K.K., is expanding Ga-68 labeled diagnostics in Japan through a clinical trial approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Utilizing Eckert & Ziegler’s GalliaPharm® generator, the trial … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Technology
Tagged clinical research project, clinical trial, computerized Tomography, diagnostics, DOTA-TATE Positron Emission Tomography, Dr. Harald Hasselmann, Eckert & Ziegler, Ga-68, GalliaPharm®, Gallium-68, Ge-68, Japan, Japanese Pharmaceuticals and Medical Devices Agency, NCT06240741, NEN, neuroendocrine neoplasms, Novartis Pharma K.K., PET, PMDA, radioisotope supply, rare tumors
(IN BRIEF) Voydeya (danicopan), a first-in-class oral Factor D inhibitor, has been recommended for marketing authorization in the European Union (EU) as an add-on to ravulizumab or eculizumab for adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who experience residual haemolytic … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, eculizumab, Marc Dunoyer, PNH, Professor Hubert Schrezenmeier, ravulizumab, safety, treatment, Voydeya
(IN BRIEF) GSK plc has announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, an oral antibiotic aimed at treating uncomplicated urogenital gonorrhoea in adolescents and adults. The trial demonstrated gepotidacin’s non-inferiority compared to the current … Read the full press release
(IN BRIEF) Boehringer Ingelheim has reported compelling results from its Phase II trial of Survodutide, a novel glucagon/GLP-1 receptor dual agonist, indicating its potential to become a leading treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). In the trial, up to 83.0% … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Carinne Brouillon, Dr. Arun Sanyal, MASH, Phase II Trial, Survodutide, treatment
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
